AstraZeneca has announced that its lung-cancer drug Enhertu has received a recommendation for approval in the European Union following positive test results. This is a significant milestone for the anglo-swedish pharmaceutical company.
Positive Test Results
Enhertu showed promising results in the tests conducted, with an objective response rate of 49.0% and a median duration of response of 16.8 months. Additionally, the tests indicated a disease control rate of 93.1%.
Targeting Advanced Non-Small-Cell Lung Cancer
The drug has been recommended as a monotherapy for the treatment of adult patients with advanced non-small-cell lung cancer who have tumors with an activating HER2 mutation. This particular form of lung cancer is aggressive and commonly affects younger patients. Unfortunately, it has a poor prognosis, with limited approved treatment options available.
Filling an Unmet Need
If approved, Enhertu will be the first targeted treatment option available for patients suffering from this specific type of lung cancer. The recognition of this unmet need in the European Union marks a significant step forward in providing better treatment options for these patients.
Enhertu is being jointly developed and commercialized in collaboration with Japan's Daiichi Sankyo.